Australian Institute for Bioengineering and Nanotechnology

The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) was established in 2003.

It is home to research groups working at the interface of the biological, chemical and physical sciences, and its applications in human health and environmental issues.

Notable work performed by the institute includes the needleless Nanopatch vaccine delivery device[2] that is ready to begin human trials;[3] local production of an experimental antibody for the treatment of the Hendra virus;[4] and biofuel research.

[9] The Jackson/S2F Architectural firm designed the building, which possesses 15,700 square metres (169,000 sq ft) of floor space, and comprises PC2 and PC3 biocontainment laboratories.

AIBN provides facilities, equipment and, through The University of Queensland's commercialisation company UniQuest, a level of specialist support, such as management of patents and commercial advice.